India Commission Seeks Comment on Sun-Ranbaxy Deal
This article was originally published in PharmAsia News
Executive Summary
An Indian regulatory body has begun accepting comments from the general public and stakeholders that will be affected by the merger of Sun Pharmaceutical Industries and Ranbaxy Laboratories.